No Data
No Data
Proteintech Genomics Launches the MultiPro Human Discovery Panel: A New Frontier in Single-Cell Multiomics
Looking Into 10x Genomics's Recent Short Interest
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics Against NanoString's CosMx SMI Products
TD Cowen Maintains 10x Genomics(TXG.US) With Hold Rating, Cuts Target Price to $18
Leerink Partners Maintains 10x Genomics(TXG.US) With Buy Rating
Strategic Pricing and Market Expansion Drive 10x Genomics Buy Rating
La Tortuga : Why. Tutes are buying. This is a long steady climb. I like seeing green in my portfolio.